How Analyst Views on Royalty Pharma Are Shifting With Recent Acquisition and Growth Moves

Royalty Pharma stock has garnered renewed attention as its fair value estimate was recently raised from $44.10 to $45.54. This indicates a modestly more optimistic outlook in the wake of its ...

Royalty Collective to Seek Early Appeal in Spotify Bundling Suit

Royalty clearinghouse Mechanical Licensing Collective told a judge it wants the Second Circuit to review a ruling that tossed ...

Permian Basin Royalty Trust: Waddell's Relaunch Uncertain Amid Bleak Oil Prospects

Permian Basin Royalty Trust is rated a Hold due to deteriorating cash distributions & challenging outlook for oil prices.
Fierce Pharma

With Ziihera wins rolling in, Zymeworks rolls out plan to become 'royalty-driven organization'

Having found swift success with its Jazz Pharmaceuticals and BeOne Medicines-licensed cancer med Ziihera, Zymeworks has ...

Websites focused on Baylor sports at odds over royalty payments

BaylorFans.com filed a lawsuit last week alleging breach of contract and fraud against the owners of SicEm365.com.

PrairieSky Royalty: Reducing It To A 'Hold' Again

Discover PrairieSky Royalty’s resilient Q3 results and dividend outlook amid lower oil prices. Learn if PSK is a buy, hold, ...